Liraglutide induces apoptosis and cell cycle arrest in breast and prostate cancer cells via GLP1R activation
Background
Breast cancer and prostate cancer are leading causes of mortality, often characterized by dysregulated cellular metabolism, including enhanced glycolysis and altered oxidative stress responses. Traditional therapies face challenges with resistance and side effects. Adipokines, signaling molecules from adipose tissue, also play a crucial role in tumor progression. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), like liraglutide, are known for metabolic benefits in type 2 diabetes and obesity, but their direct anticancer potential, particularly through modulating these metabolic pathways and adipokine profiles, remains an area of active investigation. This study explores this gap.
Study Design
Researchers investigated the anticancer effects of liraglutide in human MCF7 breast cancer and PC-3 prostate cancer cell lines. The study design focused on assessing key molecular pathways. They measured GLP1R expression, cAMP/PKA signaling activation, and evaluated antiproliferative effects, apoptosis induction, and cell cycle arrest. Gene expression analysis was performed for cell cycle regulators (CCND1, CCND3, BCL2, survivin, p21). The abstract snippet did not provide specific doses or durations of liraglutide treatment, nor did it detail methods for assessing glycolysis, oxidative stress, or adipokine profiles, despite the title indicating these were studied.